mixed phenotype acute leukemia (mpal)
Showing 1 - 2 of 2
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))
Recruiting
- Mixed Phenotype Acute Leukemia (MPAL)
- Measurable Residual Disease (MRD)
- BLINCYTO (Blinatumomab)
-
Baltimore, MarylandGreenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) Trial in United States
Completed
- Acute Myeloid Leukemia (AML)
- +3 more
- Selinexor
- +3 more
-
Phoenix, Arizona
- +5 more
Mar 25, 2020